Company news

Gilead Sciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024

October 21, 2024

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

October 18, 2024

Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024

October 8, 2024

Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

October 8, 2024

Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference

October 6, 2024

Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries

October 1, 2024

Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial

September 11, 2024

Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies

September 9, 2024

Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer

September 4, 2024

Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

August 13, 2024

Gilead Sciences Announces Second Quarter 2024 Financial Results

August 7, 2024

Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024

July 24, 2024

Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline

July 24, 2024

Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024

July 23, 2024

Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia

July 21, 2024

Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025

July 16, 2024

Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024

July 15, 2024

Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

June 19, 2024

New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment

June 13, 2024

Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA

June 5, 2024

Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis

June 4, 2024

Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

June 2, 2024

Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma

June 2, 2024

Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer

June 1, 2024

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers

May 31, 2024

EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024

May 30, 2024

Gilead Provides Update on Phase 3 TROPiCS-04 Study

May 29, 2024

Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024

May 21, 2024

Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis

May 17, 2024

Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy

May 13, 2024

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

May 8, 2024

Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024

May 6, 2024

FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV

April 25, 2024

Gilead Sciences Announces First Quarter 2024 Financial Results

April 24, 2024

Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024

April 7, 2024

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

March 27, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six

March 27, 2024

Gilead Sciences Announces Completion of Acquisition of CymaBay

March 21, 2024

Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer

March 10, 2024

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

March 5, 2024

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

March 5, 2024

New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19

March 4, 2024

Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

March 4, 2024

Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.

February 26, 2024

U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance

February 25, 2024

Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024

February 25, 2024

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

February 11, 2024

Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC

February 8, 2024

Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results

February 5, 2024

Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend

February 5, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 51 decks. Every deck is listed under its year.